We can maybe learn from surveys, which often quota sample (representation by design) and/or up-weighting the under represented in the analysis. The first is hard; the second, less so. See, e.g.: (9/20) https://t.co/7K3X6MKlDt https://t.co/sSAvLO1NW1 https:
Funding is limited for pragmatic trials but multiple strategies to ‘pragmatise’ standard RCTs to be more similar to routine care - but still lots of uncertainties about best practice. This is a nice example from IMI GET-REAL https://t.co/A59BKU7pDC
New on https://t.co/8pxKdRDxAR | The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials | https://t.co/8J0V2T2gHE